- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05577455
Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients
October 26, 2022 updated by: Peking University Third Hospital
Non-inferiority Randomized Controlled Study on Kidney Tonifying and Blood Circulation Regulating Therapy (Bu Shen Tiao Xue) of Different Intervention Courses in Improving IVF-ET Pregnancy Outcomes in DOR Patients
Patients with diminished ovarian reserve (DOR) who undergo in vitro fertilization and embryo transfer (IVF-ET) are included as the research subjects.
The effects of Traditional Chinese Medicine (TCM) for kidney tonifying and blood circulation regulating of different intervention courses on ovarian hyporesponsiveness, IVF-ET outcome and clinical compliance in DOR patients are studied by a non-inferiority randomized controlled trial.
The purpose is to identify the breakthrough point and treatment timing of TCM treatment, explore the best treatment course of TCM, and optimize the TCM therapeutic regimen.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
IVF-ET is one of the major techniques to treat infertility in DOR patients, but poor ovarian response and low pregnancy rate have been the bottleneck problems.
China has original advantages in Traditional Chinese Medicine (TCM) treatment.
The kidney tonifying and blood circulation regulating therapy is a pre-IVF-ET intervention treatment characterized by sequential treatment according to menstrual cycle formed in the previous investigations by the research group.
It can ameliorate ovarian hyporesponsiveness and improve the success rate of IVF-ET, but the compliance is poor due to the long intervention course.
Identifying the time point of TCM intervention to further optimize the treatment plan is the key to improving the pregnancy rate.
Therefore, DOR patients who receive IVF-ET are enrolled as the research objects in this project, who are divided into the experimental group and control group with a randomized controlled non-inferiority design, and receive sequential TCM therapy for kidney tonifying and blood circulation regulating from the fifth day of menstruation at the second menstrual cycle and the third menstrual cycle prior to IVF-ET, respectively, until the day of human chorionic gonadotrophin (hCG) administration.
The number of oocytes retrieved, the rate of high-quality embryos, the dosage and administration days of Gn, the levels of estradiol (E2) and progesterone (P) and the clinical pregnancy rate on hCG day are compared between the two groups.
Meanwhile, the compliance of patients in the two groups with different treatment regimens is compared.
This project aims to verify that the efficacy of the treatment plan implemented from the second menstrual cycle prior to IVF-ET may not be inferior to that from the third menstrual cycle prior to IVF-ET on improving the pregnancy outcomes of DOR patients, while the compliance is better.
The results of the study will provide a reference basis for the precise treatment of TCM prior to IVF-ET.
Study Type
Interventional
Enrollment (Anticipated)
266
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiyan Xin
- Phone Number: 4621 +86 0108226
- Email: xinxiyan198234@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 42 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female, 20 years old ≤ age ≤ 42 years old;
- The menstrual cycle is generally regular; 21 days < menstrual cycle < 35 days;
- Those who meet the diagnostic criteria for DOR in Western medicine;
- Those who meet the TCM differential criteria of kidney deficiency syndrome;
- Those who are scheduled to undergo IVF-ET;
- Those who voluntarily participate in this clinical trial and sign a written informed consent.
Exclusion Criteria:
- Those who have a history of two or more spontaneous abortions (excluding biochemical pregnancy abortion) or three or more previous transplantations without achieving clinical pregnancy;
- Those who have premature ovarian failure or ovarian gonadotropin resistance syndrome;
- Those who have untreated uterine malformation or abnormality: double uterus, septate uterus (complete or incomplete);
- Those who have untreated unilateral or bilateral hydrosalpinx;
- Those who have uncured endometrial diseases (such as endometritis, endometrial polyps, endometriosis), adenomyosis, intrauterine adhesions, etc., and those with uterine fibroids of more than 4 cm;
- Those who have endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, hypothyroidism, abnormal adrenal function, etc., which affect ovulation;
- Infertile patients with abnormal ovarian function caused by immunological factors, genetic factors or congenital physiological defects;
- Those who have received pelvic radiotherapy;
- Those who are known or suspected of having sex hormone-related malignant tumors;
- Those who are allergic or intolerable to the medications involved in the study;
- Those with contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormal liver and renal function, diabetes, hypertension, thyroid disease, symptomatic heart disease, moderate to severe anemia, history of malignant tumor or history of thromboembolism or thrombosis formation tendency, serious mental illness, acute infection of urogenital system, sexually transmitted disease, extremely bad habits such as drug use, exposure to teratogenic radiation, poison, drugs (such as prednisone and other hormones, epinephrine, antibiotics, antihypertensive drugs, cardiovascular and cerebrovascular drugs, antiviral drugs) and are still under the effect of the drugs; and those whose uterus is unable to perform the function of pregnancy or who are intolerant of pregnancy due to physical diseases during pregnancy;
- Those who have taken other TCMs or proprietary Chinese medicines that can invigorate the kidney or affect the evaluation of drug efficacy in the past 30 days;
- Other patients who are deemed unsuitable to participate in this study by the researchers;
- Those who are participating in other clinical trials;
- Those who do not agree to participate in this study or do not sign the informed consent form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: administration for 2 menstrual cycles group
This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.
|
Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni).
The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome).
The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
|
ACTIVE_COMPARATOR: administration for 3 menstrual cycles group
This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.
|
Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni).
The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome).
The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of oocytes retrieved
Time Frame: up to 15 weeks from enrollment
|
The number of oocytes retrieved by puncture under the guidance of vaginal ultrasound
|
up to 15 weeks from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
High-quality embryo rate (%)
Time Frame: up to 15 weeks from enrollment
|
Number of high-quality embryos / the total number of normal cleavage embryos × 100%
|
up to 15 weeks from enrollment
|
Clinical pregnancy rate
Time Frame: up to 15 weeks from enrollment
|
Ultrasound monitoring is performed 30 days after embryo transfer
|
up to 15 weeks from enrollment
|
Compliance with the treatment plan
Time Frame: up to 15 weeks from enrollment
|
The situation of continuous treatment of the research subjects is recorded; the compliance of the experimental group = the number of cases who receive continuous treatment for 2 months / the total number of patients in the experimental group; the compliance of the control group = the number of cases who receive continuous treatment for 3 months / the total number of patients in the control group
|
up to 15 weeks from enrollment
|
Gonadotrophin (Gn) administration day
Time Frame: up to 15 weeks from enrollment
|
Record the total gonadotrophin (Gn) administration day
|
up to 15 weeks from enrollment
|
Gn dosage
Time Frame: up to 15 weeks from enrollment
|
Record the average dose of Gn administration
|
up to 15 weeks from enrollment
|
Levels of LH
Time Frame: up to 15 weeks from enrollment
|
Obtained by blood sampling
|
up to 15 weeks from enrollment
|
Levels of E2
Time Frame: up to 15 weeks from enrollment
|
Obtained by blood sampling
|
up to 15 weeks from enrollment
|
Levels of P
Time Frame: up to 15 weeks from enrollment
|
Obtained by blood sampling
|
up to 15 weeks from enrollment
|
Antral follicle count (AFC)
Time Frame: up to 15 weeks from enrollment
|
Changes of AFC before and after TCM intervention
|
up to 15 weeks from enrollment
|
Levels of FSH
Time Frame: up to 15 weeks from enrollment
|
Obtained by blood sampling
|
up to 15 weeks from enrollment
|
Levels of AMH
Time Frame: up to 15 weeks from enrollment
|
Obtained by blood sampling
|
up to 15 weeks from enrollment
|
Health economics indicators
Time Frame: up to 15 weeks from enrollment
|
Average daily cost and total cost
|
up to 15 weeks from enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 10, 2022
Primary Completion (ANTICIPATED)
December 30, 2024
Study Completion (ANTICIPATED)
December 30, 2024
Study Registration Dates
First Submitted
October 9, 2022
First Submitted That Met QC Criteria
October 9, 2022
First Posted (ACTUAL)
October 13, 2022
Study Record Updates
Last Update Posted (ACTUAL)
October 27, 2022
Last Update Submitted That Met QC Criteria
October 26, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00006761-M2022270
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Cairo UniversityCompleted
-
Navy General Hospital, BeijingUnknownFemale Infertility Due to Nonimplantation of OvumChina
-
Woman's Health University Hospital, EgyptCompletedFemale Infertility Due to Diminished Ovarian ReserveEgypt
-
Woman's Health University Hospital, EgyptCompleted
-
The University of Hong KongCompletedFemale Infertility Due to Diminished Ovarian ReserveHong Kong
Clinical Trials on Medical prescription before ovulation
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Unknown
-
Spectrum Health HospitalsPrimus PharmaceuticalsWithdrawnVaricose Veins | Venous Insufficiency of Leg | Venous Reflux | Lower Extremity Edema ChronicUnited States
-
Universidad de GranadaRecruiting
-
Groupe Hospitalier Paris Saint JosephWithdrawn
-
Francisco MaduellFresenius Medical Care EuropeCompleted
-
Mclean HospitalUniversity of California, Los AngelesCompletedSubstance-related Disorders | Opioid-related Disorders | Opiate DependenceUnited States
-
Universidad de GranadaAsociación Española contra el CáncerRecruiting
-
Aljazeera HospitalUnknown
-
Alison GustafsonInstacart Health; Kentucky Association of Health PlansRecruitingType 2 Diabetes Mellitus | Gestational Diabetes Mellitus in PregnancyUnited States
-
Massachusetts General HospitalCambridge Health Alliance; MaineHealthRecruitingPain | Marijuana Use | Opioid UseUnited States